indium in 111 anti-cd45 monoclonal antibody bc8

Indium In 111 Anti-CD45 Monoclonal Antibody BC8 is a radioimmunoconjugate composed of the murine IgG1 monoclonal antibody BC8, which targets the CD45 antigen present on all hematopoietic cells except mature erythrocytes and platelets. The BC8 antibody is conjugated to a chelator (DOTA) and radiolabeled with the gamma-emitting isotope Indium-111. This agent is primarily used as an imaging tracer to assess biodistribution and dosimetry prior to therapeutic administration of Yttrium-90-labeled BC8 for conditioning regimens before hematopoietic stem cell transplantation in patients with hematologic malignancies such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), lymphoma, and multiple myeloma. The mechanism involves specific binding to CD45 on target cells, allowing targeted delivery of radiation for imaging or therapy[1][2][3][5][6].

Other names

indium-111-labeled anti-cd45 antibody bc8indium111-labeled anti-cd45 antibody bc8indium 111-labeled anti-cd45 antibody bc8111in-dota-anti-cd45 antibody (bc8)radioimmunoconjugate bc8